Navigation Links
Carbapenem Drug Class Shows an Increase in Hospital Inpatient Courses in Europe
Date:11/6/2008

Just Over One-Third of All Carbapenem Courses Are Used as Documented/Confirmed Therapy, According To New Data from Arlington Medical

Resources

MALVERN, Pa., Nov. 6 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that in the January -- June 2008 time period, the carbapenem drug class in hospital inpatient courses in Europe has grown seven percent compared to the January -- June 2007 time period. These antibiotics are commonly used to treat lower respiratory infections, systemic infections, abdominal/pelvic infections and GI/biliary infections.

"Among carbapenem antibiotics Merck's Primaxin/Tienam (imipenem/cilastatin) has the largest share of courses (54 percent), followed by AstraZeneca's Merrem/Meronem (meropenem) (36 percent) and Merck's Invanz (ertapenem injectable) (10 percent)," stated Joyce Wedemeyer, product director at AMR. "These shares are consistent with our prior audit for the January -- June 2007 time period."

The newly released European edition of The Hospital Antibiotic Market Guide also finds that just over one-third of all carbapenem courses are used as documented/confirmed therapy. Inpatients treated with a carbapenem course in a documented/confirmed case are most commonly associated with escherichia coli (29 percent of documented courses), pseudomonas aeruginosa (20 percent), methicillin-sensitive staphylococcus aureus (9 percent) and enterococcus faecalis (8 percent).

Why Pharmaceutical Companies Need this Information

The Hospital Antibiotic Market Guide enables pharmaceutical companies to monitor patient shares, costs, infectious disease prevalence and the clinical use of antibiotics in acute care hospitals. In addition, pathogen-level details are available for those inpatient antibiotic drug courses associated with positive microbiological culture results.

About The Hospital Antibiotic Market Guide

The Hospital Antibiotic Market Guide is the industry's most comprehensive audit of inpatient antibiotic usage covering acute care hospitals in the United States, Italy, Germany, France, U.K. and Spain. The information in the audit is abstracted directly from hospital source documents from a panel of demographically representative acute care hospitals of all sizes, including transplant centers. The U.S. data is published twice a year and the European data is published once a year.

About AMR

AMR (http://www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Natalia Morales Elizabeth Marshall

Decision Resources Decision Resources, Inc.

781-296-2691 781-296-2563

nmorales@dresources.com emarshall@dresources.com


'/>"/>
SOURCE Arlington Medical Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Kingfisher Healthcare (KFH) Achieves World Class Quality Platform
2. ADDA Kicks Off AD/HD Awareness Campaign with Four Regional Conferences Beginning Sept. 29 and Series of Fall Teleclasses
3. A classic method for modeling skin cancer is featured in Cold Spring Harbor Protocols
4. First Circuit Court of Appeals Rules Against Philip Morris in Lights Class Action
5. Theater Classes Help Docs Bedside Manners
6. Tarpinian: Misclassification is Theft
7. New class of RNA molecules may be important in human cancer
8. Instrumentation Laboratory Named Top of Class by Respiratory Care Managers
9. Consumer Group: Hillary Clintons Mandatory Health Insurance Purchase Plan is an Act of War on the Middle Class Family That Cant Afford $12k Policy
10. SATELLITE BROADCAST: Consumer Group Says Hillary Clintons Mandatory Health Insurance Plan is an Act of War on the Middle Class that Cant Afford $12k Policy
11. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against LCA-Vision Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... While it’s ... poses a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , ... medication in darkness or restricted lighting. As such, it eliminates the need to turn ...
(Date:10/13/2017)... , ... October 13, 2017 , ... PurhealthRX , ... Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize ... providing a CBD form that can be easily incorporated into liquid products, while reducing ...
(Date:10/13/2017)... Shelton, CT (PRWEB) , ... October 13, 2017 , ... ... and long-term care services, staged a mock evacuation of the facility as part of ... Department, Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well ...
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
(Date:9/12/2017)... PARIS and NEW YORK , Sept. 12, ... ethical performance ratings for global supply chains, has published the first annual ... the CSR performance of more than 20,400 companies evaluated by EcoVadis, based ... years 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
Breaking Medicine Technology: